These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
548 related articles for article (PubMed ID: 25134325)
1. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions. Sandler S Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325 [TBL] [Abstract][Full Text] [Related]
2. [Multimodality therapy for adenocarcinoma of the esophagogastric junction]. He J; Huang JF Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Sep; 15(9):877-80. PubMed ID: 22990915 [TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness in esophagogastric cancer. Knab LM; Belotte J; Munshi HG; Bentrem DJ Cancer Treat Res; 2015; 164():121-42. PubMed ID: 25677022 [TBL] [Abstract][Full Text] [Related]
4. Treatment approaches to esophagogastric junction tumors. Kurokawa Y; Sasako M; Doki Y Dig Surg; 2013; 30(2):169-73. PubMed ID: 23867594 [TBL] [Abstract][Full Text] [Related]
5. (Neo)-adjuvant chemo(-radio) therapy for adenocarcinomas of the gastroesophageal junction and the stomach in the West. Wilke H; Lordick F; Meyer HJ; Stahl M Dig Surg; 2013; 30(2):112-8. PubMed ID: 23867587 [TBL] [Abstract][Full Text] [Related]
6. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG). Shen J; Zhu X; Du Y; Zhu Y; Yu P; Yang L; Xu Z; Huang L; Zhang Y; Zhang Y; Liu L; Cheng X Trials; 2021 Oct; 22(1):753. PubMed ID: 34717717 [TBL] [Abstract][Full Text] [Related]
8. Diagnosis and treatment of non-metastatic esophagogastric junction adenocarcinoma: what are the current options? Gronnier C; Piessen G; Mariette C J Visc Surg; 2012 Feb; 149(1):e23-33. PubMed ID: 22341763 [TBL] [Abstract][Full Text] [Related]
9. Controversies in the treatment of local and locally advanced gastric and esophageal cancers. Cohen DJ; Leichman L J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? Moorcraft SY; Smyth EC; Cunningham D Gastric Cancer; 2015 Jan; 18(1):1-10. PubMed ID: 24638977 [TBL] [Abstract][Full Text] [Related]
11. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M; Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827 [TBL] [Abstract][Full Text] [Related]
12. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma. Fernandez E; Cacheux W; Frossard JL; Koessler T; Abou M; Moniez M; Huber O; Puppa G; Roth A Dig Liver Dis; 2017 May; 49(5):552-556. PubMed ID: 28179095 [TBL] [Abstract][Full Text] [Related]
13. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Lutz MP; Zalcberg JR; Ducreux M; Ajani JA; Allum W; Aust D; Bang YJ; Cascinu S; Hölscher A; Jankowski J; Jansen EP; Kisslich R; Lordick F; Mariette C; Moehler M; Oyama T; Roth A; Rueschoff J; Ruhstaller T; Seruca R; Stahl M; Sterzing F; van Cutsem E; van der Gaast A; van Lanschot J; Ychou M; Otto F; Eur J Cancer; 2012 Nov; 48(16):2941-53. PubMed ID: 22921186 [TBL] [Abstract][Full Text] [Related]
14. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115 [TBL] [Abstract][Full Text] [Related]
15. [Adjuvant treatment for esophagogastric junction cancer]. Kurokawa Y; Takiguchi S; Miyazaki Y; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Mori M; Doki Y Nihon Geka Gakkai Zasshi; 2015 Jan; 116(1):50-4. PubMed ID: 25842814 [TBL] [Abstract][Full Text] [Related]
16. Cancer of the gastroesophageal junction: combined modality therapy. Ilson DH Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275 [TBL] [Abstract][Full Text] [Related]
17. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531 [TBL] [Abstract][Full Text] [Related]
18. [Role of postoperative chemoradiotherapy in the therapeutic management of adenocarcinomas of the stomach and oesogastric junction]. Ben Salah H; Bahri M; Dhouib F; Daoud J Cancer Radiother; 2016 Dec; 20(8):830-832. PubMed ID: 27793531 [TBL] [Abstract][Full Text] [Related]
19. Current Management of Locally Advanced Junction Esophagogastric Adenocarcinoma. Birla R; Hoara P; Caragui A; Cristian M; Constantinoiu S Chirurgia (Bucur); 2018; 113(1):38-45. PubMed ID: 29509530 [TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. Lagarde SM; ten Kate FJ; Reitsma JB; Busch OR; van Lanschot JJ J Clin Oncol; 2006 Sep; 24(26):4347-55. PubMed ID: 16963732 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]